- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07810647
Effectiveness of Shared Decision Making(SDM)on Patients With Poor Control Type 2 Diabetes (SDM)
Studienübersicht
Detaillierte Beschreibung
Background Diabetes and hyperglycemia not only increase the risk of complications of cardiovascular disease and lead to a situation involving exposure to danger of death. Meanwhile, the patient's self-management is one of the key factors affecting the quality control of blood sugar. Thereby, Shared Decision Making (SDM) is a patient-centered medical implementation method that healthcare professionals and patients jointly participate in treatment decision-making to reach a consensus, which can stimulate the health care ability of participants to achieve treatment goals.
Purpose: This research aims to implement the SDM model based on self-efficacy theory through individualized decision-making to strengthen the behavioral motivation of diabetic patients and finally, to improve the patient's health promotion behavior and the effectiveness of blood sugar control.
Method: Study Type: Interventional Actual Enrollment:76 participants Allocation:Randomized Intervention Model:Parallel Assignment Masking:Single(Participant)
Expected results:
It is hoped that the implementation of SDM model will be used to strengthen the behavioral motivation of diabetic patients through individualized decision-making, and to confirm whether it can effectively improve the patient's health behavior and the effectiveness of disease control.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Taiwan
-
Tainan, Taiwan, Taiwan, 709204
- An Nan Hospition-China Medical University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Aged>20y/o
- Diagnosed by a physician as type 2 diabetes
- The Diabetes Participated in the Diabetes Shared Care Network
- Glycosylated hemoglobin (A1C)> 7.5%
- Can communicate in Chinese or Taiwanese.
Exclusion Criteria:
- People with mental or cognitive impairment who cannot communicate
- Health Literacy score lower than 6 points
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Control group:as usual care
The control group received as usual care.
|
|
|
Experimental: Experimental group:The intervention of SDM
The experimental group received the intervention of SDM 3 times for 3 months,
|
The experimental group received the intervention of SDM 3times/month for 3months, then follow the health promotion behavior compliance by phone once a month.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diabetes self-efficacy scale
Zeitfenster: Pre-test (baseline)
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
Pre-test (baseline)
|
|
Diabetes self-efficacy scale
Zeitfenster: 1 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
1 months after intervnetion
|
|
Diabetes self-efficacy scale
Zeitfenster: 3 months after intervnetion
|
assesses the confidence of diabetes patients in their ability to manage their diet, blood sugar, and physical exercise
|
3 months after intervnetion
|
|
Diabetes health literacy scale
Zeitfenster: Pre-test (baseline)
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
Pre-test (baseline)
|
|
Diabetes health literacy scale
Zeitfenster: 3 months after intervnetion
|
A disease-specific scale to measure functional, communicative and critical health literacy in primary care
|
3 months after intervnetion
|
|
Diabetes health promotion scale
Zeitfenster: Pre-test (baseline)
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
Pre-test (baseline)
|
|
Diabetes health promotion scale
Zeitfenster: 1 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
1 months after intervnetion
|
|
Diabetes health promotion scale
Zeitfenster: 3 months after intervnetion
|
A self-report study instrument that includes the health profile, and Diabetes Health Promotion Scale
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Zeitfenster: 3 months after intervnetion
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months.
|
3 months after intervnetion
|
|
Hemoglobin A1C (HbA1c) Test
Zeitfenster: Pre-test (baseline)
|
An HbA1c test shows what the average amount of glucose attached to hemoglobin has been over the past three months
|
Pre-test (baseline)
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- FooyinU
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .